Acumen Pharmaceuticals posts narrower Q3 loss and expects Alzheimer’s Phase II readout in November
Acumen Pharmaceuticals reported third‑quarter 2026 results with an adjusted loss of $0.35 per share, beating consensus. Net loss narrowed to $25.4 million and cash stood at $78.6 million, which management says will fund operations into early 2027. The company reaffirmed its timeline to release top‑line data from the ALTITUDE‑AD Phase II Alzheimer’s trial in November 2026 and to file an IND for its enhanced‑brain‑delivery program in mid‑2027.
Why it matters
The cash balance of $78.6 million is expected to sustain clinical and operating activities through early 2027, limiting the need for immediate financing. The reduced loss and earnings beat drove a pre‑market share rise of about 5.5 percent.
Key facts
- 1Adjusted loss per share was $‑0.35, beating the consensus estimate of $‑0.38 by $0.03. investing.com
- 2Net loss for the quarter was $25.4 million. investing.com
- 3Cash, cash equivalents and marketable securities were $78.6 million as of September 30, 2026. investing.com
- 4Research and development expenses were $21.1 million. investing.com
- 5General and administrative expenses were $4.7 million. investing.com
- 6Top‑line results from the ALTITUDE‑AD Phase II study are expected in November 2026. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.